𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy of Irbesartan, a Receptor Selective Antagonist of Angiotensin II, in Reducing Portal Hypertension

✍ Scribed by Wilma Debernardi-Venon; Claudio Barletti; Carlo Alessandria; Alfredo Marzano; M. Baronio; Luca Todros; Giorgio Saracco; Alessandro Repici; Mario Rizzetto

Book ID
110324176
Publisher
Springer US
Year
2002
Tongue
English
Weight
192 KB
Volume
47
Category
Article
ISSN
0163-2116

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Loss of angiotensin-II receptors in port
Loss of angiotensin-II receptors in portal hypertensive rabbits
✍ James V. Sitzmann; Yuping Wu; Greti Acuilera; Paul A. Cahill; R. Cartland Burns πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 690 KB

Decreased splanchnic vascular response to exogenous angiotensin-I1 (A-11) infusion in portal hypertension has recently been documented. A-II receptor density and binding affinity in the mesenteric artery, portal vein, and adrenal gland of normal and portal hypertensive rabbits were studied. Portal h

Effect of losartan, an Angiotensin II re
Effect of losartan, an Angiotensin II receptor antagonist, on portal pressure in cirrhosis
✍ Arved Winfried Schneider; Johann Friedrich Kalk; Christian Peter Klein πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 163 KB πŸ‘ 1 views

Administration of angiotensin II causes an increase in portal pressure, and plasma concentration of angiotensin II is elevated in patients with cirrhosis, suggesting that angiotensin II may be involved in the pathogenesis of portal hypertension in cirrhosis. We evaluated the effect of the orally act

Therapeutic efficacy of an angiotensin I
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis
✍ Shiro Yokohama; Masashi Yoneda; Masakazu Haneda; Satoshi Okamoto; Mituyoshi Okad πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 1 views

The therapeutic efficacy of angiotensin II receptor antagonist, losartan, was studied in patients with nonalcoholic steatohepatitis (NASH). Seven patients with both NASH and hypertension were treated with losartan (50 mg/d) for 48 weeks. Treatment with losartan resulted in a significant decrease in